Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Participants in Asia With Early Triple-Negative Breast Cancer An Updated Subgroup Analysis of the KEYNOTE-522 Randomized Clinical Trial

Study limitation reported by the research below: “Study design tag reflects this being a subgroup analysis of an RCT, which carries inherent limitations in interpretability; level of evidence assigned as 2 given the RCT source but exploratory subgroup nature should be noted.”